Gmax values all kinds of partnerships that help the company to grow. To support the clinical development of the two leading programs, Gmax is seeking the B-round financing in the near-term. For more information, please contact:


Dedicated in GPCR antibody development, Gmax is committed to partnerships with biotech and pharmaceutical companies in cardiovascular diseases, metabolic disorders and cancer. Gmax is open to various opportunities like out-licensing and co-development on a global basis. To leverage the GPCR mAb platform technology, we are also seeking strategic partnership focusing on targets of mutual interests. Together with the partners, Gmax aims to advance the pipeline and to provide better treatments to patients worldwide. For business development opportunities, please contact: